This is our primary end point: Clinical Improvement as

New Post Public Reply Private Reply Replies (0) Message Board
TechGuru
896
This is our primary end point:

Quote:
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) [ Time Frame: Day 14 ]
Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. [0=none, 1=mild, 2=moderate, and 3=severe]. Higher scores mean a worse outcome.


These are some of our Secondary end-points:

Quote:
Time to clinical resolution (TTCR) [ Time Frame: Day 14 ]

Change from baseline in National Early Warning Score 2 (NEWS2) [ Time Frame: Days 3, 7, and 14 ]
This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). Higher scores mean a worse outcome.


So ... below some copy-and-paste

https://www.cebm.net/covid-19/should-we-use-t...mary-care/

https://www.mdcalc.com/national-early-warning-score-news-2


NEWS uses six physiological measurements: respiratory rate; oxygen saturation; temperature; systolic blood pressure; heart rate and level of consciousness. Each scores 0–3 and individual scores are added together for an overall score. An additional two points are added if the patient is receiving oxygen therapy. The total possible score ranges from 0 to 20. The higher the score the greater the clinical risk. Higher scores indicate the need for escalation, medical review and possible clinical intervention and more intensive monitoring.
NEWS2 was released in 2017.7 This measured the same six physiological measures but the layout of the chart was changed to align with the Resuscitation Council (UK) ABCDE sequence.8 The section for recording the rate of oxygen and the device used has been improved. The section measuring level of consciousness has added ‘new confusion’ (which includes disorientation, delirium or any new alteration to mentation) to the AVPU score, which becomes ACVPU (where C represents confusion). The importance of considering serious sepsis in patients with known or suspected infection, or at risk of infection, is emphasized.

Patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group (50% vs 20%; p=0.0223).

What does this mean ??? imho that we are better when treating moderate patients than mild patients . The NEWS2 score includes the temperature (fever) and the dyspnea term in which it measures oxygen saturation (arguably lower than normal if one has dyspnea). Our primary end point measures this as well as cough and muscle pain.

In essence, the NEWS2 score will differentiate a more a severe patient as compared to a mild one. And we got a statistical significant p-value !!!!

This is big. As a matter of fact, Lopinavir–Ritonavir (Abbott, Abbvie) used the NEWS 2 score for their (failed) SEVERE trial:

https://www.nejm.org/doi/pdf/10.1056/NEJMoa20...Tools=true

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 8

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 5

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 39

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Amicus Therapeutics Plans Third Quarter 2025 Earnings Call

Updated Category News Views 159

Amicus Therapeutics to Discuss Q3 2025 Financial Results Amicus Therapeutics (NASDAQ: FOLD) is preparing for an important financial discussion as it will host a conference call on November 4, 2025, at 8:30 a.m. ET. This call aims to provide insights into the company’s financial performance for the quarter ending September 30, 2025. Conference Call Participation...

Continue Reading
Cineplex Inc. Hits New Milestones In Q2 2025 Financials

Updated Category News Views 223

Cineplex Reports Impressive Growth in Second Quarter Financials Cineplex Inc. (TSX: CGX) has announced its financial performance for the second quarter of 2025, revealing remarkable growth across various metrics. The company’s total revenues surged to CAD 361.8 million, representing a robust 30.5% increase compared to the same period last year. This performance can be...

Continue Reading
Pinnacle Mergers & Acquisitions Finalizes $151M Deal with Dream Motor Group

Updated Category News Views 545

Pinnacle Mergers & Acquisitions Completes a Major Sale DALLAS — Pinnacle Mergers & Acquisitions, a premier automotive buy-sell advisory firm, has finalized the significant sale of Toyota of Montgomery and Lexus of Montgomery to the renowned Dream Motor Group, led by famed coach Nick Saban and automotive expert Joe Agresti. The deal is valued at an impressive $151...

Continue Reading
Atria Development Corporation Appoints New Vice President

Updated Category News Views 80

Atria Development Corporation Welcomes New Leadership Atria Development Corporation is thrilled to announce that Durval Terceira has been appointed as the new Vice President of Business Development and Labour Relations. With his impressive background, he brings a wealth of experience that is expected to steer the company towards its future goals. Durval Terceira: An...

Continue Reading
Ark Invest's Strategic Shift: Selling Block Inc. Shares

Updated Category News Views 289

Ark Invest Adjusts Its Strategy Cathie Wood's Ark Invest has recently made headlines by selling off a portion of its holdings in Block Inc. This decision, valued at an impressive $4.8 million, signifies a potential shift in investment strategy ahead of Block's forthcoming earnings report. Investors are closely monitoring this move as it coincides with Block's rising...

Continue Reading